Related Experiment Video

Updated: Jun 1, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Glycogen synthase kinase-3β: a mediator of inflammation in Alzheimer's disease?

Jari Koistinaho1, Tarja Malm, Gundars Goldsteins

  • 1Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.

International Journal of Alzheimer'S Disease
|June 2, 2011
PubMed

Insights

Glycogen synthase kinase-3β regulates microglial immune responses in the brain. This review explores its role in Alzheimer's disease neuroinflammation, highlighting its potential impact on disease pathology.

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Microglial cells are key immune responders in the central nervous system, crucial for brain health.
  • Sustained microglial activation contributes to neuroinflammation and neuronal damage, characteristic of neurodegenerative diseases like Alzheimer's disease (AD).
  • Glycogen synthase kinase-3β (GSK-3β) is recognized as a regulator of immune responses in microglia.

Purpose of the Study:

  • To review and discuss the role of glycogen synthase kinase-3β (GSK-3β) in microglial immune responses.
  • To explore the significance of GSK-3β in the context of Alzheimer's disease neuroinflammation and pathology.

Main Methods:

  • Literature review and synthesis of existing research on GSK-3β, microglia, and Alzheimer's disease.
  • Analysis of the molecular mechanisms linking GSK-3β to inflammatory pathways in immune cells of the brain.

Main Results:

  • Glycogen synthase kinase-3β (GSK-3β) plays a significant role in mediating inflammatory responses within microglia.
  • While GSK-3β is studied in relation to tau and amyloid-beta pathology, its specific role in AD-associated neuroinflammation is less understood.
  • The enzyme's involvement in immune cell function suggests a potential link to Alzheimer's disease pathogenesis.

Conclusions:

  • Glycogen synthase kinase-3β (GSK-3β) is a critical regulator of microglial inflammatory activity.
  • Further investigation into GSK-3β's role in neuroinflammation is warranted to understand its contribution to Alzheimer's disease.
  • Targeting GSK-3β may offer a novel therapeutic strategy for managing Alzheimer's disease.

More Related Videos

Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System09:52

Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System

Published on: December 28, 2017

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...